Consumo de rituximab y trastuzumab en la Unidad de Mezclas Oncológicas del Hospital Almanzor Aguinaga Asenjo - Chiclayo 2018

The objective of this report was to determine the consumption of rituximab and trastuzumab in the Oncological Mixtures Unit of the Almanzor Aguinaga Asenjo - Chiclayo Hospital during 2018. The results showed that trastuzumab was the most widely used monoclonal antibody with 747 units, while the Annual consumption of rituximab 100 mg was 317 units and rituximab 500 mg was 540 units dispensed. Likewise, the consumption of rituximab expressed in grams of medication per 100 patients had an annual average of 3,10 g per hundred patients, where the month of greatest consumption was August with 3.48 g/patients. The average annual consumption of trastuzumab was 1,58 g per one hundred patients, where the month of greatest consumption was February with 1,82 g/patients. Trastuzumab was the monoclonal antibody that generated the highest annual cost of S/ 3 527 393.76, being the month of July the highest cost with S / 354 156,00, while rituximab had an annual cost of S/ 1 484 299,09, where the month with the highest cost was December with S/ 167 567,09. The consumption of rituximab and trastuzumab showed a statistically significant linear trend with values of p<0,0001 and decreasing in time